to responses to synovial crystals are more pronounced in elderly patients or not is unknown.

**Objectives**: To test the hypothesis whether aging associates with a more pronounced synovial inflammation in response to urate and CPPD crystals.

**Methods**: Gout or CPPD patients with a synovial fluid (SF) aspiration were included. Clinical, blood and synovial parameters were recorded. In the Cytokine study, SF was analyzed for interleukin (IL)-1beta, IL-6, IL-8, IL-10, IL-12p70, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), IL-17, and transforming growth factor-beta (TGF-beta) by multiplexed cytokine analysis. In the Cell study, SF samples were immunophenotyped by flow cytometry, including surface markers CD4+ (CD3+), CD8+ (CD3+), and following stimulation for intracellular IFN-gamma and IL-17. The patients were divided into two groups by age median-split, respectively.

**Statistical analysis**

Categorical variables were reported as frequencies. Continuous variables were compared using Student’s t-test or in case of non-normal distribution Mann-Whitney U test.

**Table 1. Patients Characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Median (IQR)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>76.6 (69.5; 83.0)</td>
<td>0.0129</td>
</tr>
<tr>
<td>Age Median Split</td>
<td>75</td>
<td>65</td>
</tr>
<tr>
<td>Male</td>
<td>80.0%</td>
<td>68%</td>
</tr>
<tr>
<td>Gout; CPPD patients</td>
<td>10; 5</td>
<td>10; 9</td>
</tr>
<tr>
<td>Crystals*</td>
<td>7</td>
<td>8</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.1442

AB0918 FACTORS ASSOCIATED WITH ACHIEVEMENT OF TARGET SERUM URIC ACID IN PATIENTS WITH NON-TOPHACEOUS GOUT ATTENDING PRIMARY CARE CLINICS.

H. Baharudin1, S. P. Gan2, S. S. Chng2, M. Mohd Zain3. 1Universiti Teknologi MARA, Faculty of Medicine, Selangor, Malaysia; 2Hospital Selangor, Rheumatology Unit, Selangor, Malaysia

**Background:** Gout is characterised by deposition of monosodium urate crystal in the synovial fluid of joint and other tissues, in the presence of elevated serum uric acid (SUA). Dose-escalation strategy with allopurinol as first-line urate lowering therapy (ULT) was shown to be cost effective and a target SUA of less than 360µmol/L was recommended in non-tophaceous gout. Some of the barriers to treatment effectiveness were related to physician and patient-related factors.

**Objectives:** To investigate the factors associated with achievement of target SUA in patients with non-tophaceous gout attending primary care clinics.

**Methods:** A cross-sectional study was conducted over four months on patients with gout attending 21 primary care clinics in Selangor, an urbanised state in Malaysia. The demographic and clinical data, including the most recent SUA within six months of study participation, were obtained from patients’ interview and medical records. Obesity was defined as body mass index (BMI) of >27.8kg/m². Data was analysed for patients with non-tophaceous gout. Comparison between patients who achieved and did not achieve target SUA, defined as <360µmol/L, was performed using chi-square and student t-test for categorical and continuous variables.

**Results:** Four hundred and twenty-six patients with gout participated in this study and 343 (84.7%) patients had non-tophaceous gout. Their mean age was 77.7 (±12.9) years. Majority were men (260 patients), Malay (260 patients) and had at least a secondary education (223 patients). There were high prevalence of cardiovascular co-morbidities; hypertension in 279 (81.3%), dyslipidaemia in 235 (68.5%), diabetes mellitus in 154 (44.9%) and obesity in 167 of 263 (63%). There were 280 patients diagnosed with gout for more than six months and 201 (71.6%) had recent SUA; 44 (21.9%) achieved target SUA and 157 (78.1%) did not achieve target SUA. The factors found to be significantly different between the two groups were age, ethnicity, education level, BMI and SUA level before ULT initiation. (Table 1) The mean allopurinol dose were similar between patients who achieved and did not achieve target SUA (191.3±80.8mg vs 197.1±72.5mg, p=0.56) despite significant difference in the mean SUA (301.5±70.3µmol/L vs 488.3±93.1µmol/L, p<0.01).

**Conclusion:** There was a low percentage of patients who achieved target SUA in primary care clinics. Older age, ethnicity other than Malay, lower BMI and lower SUA level before ULT initiation were significantly associated with achievement of target SUA. Higher education was significantly associated with failure to achieve target SUA and in these patients, allopurinol was not titrated according to SUA level.

**Disclosure of Interests:** None declared

**References:**


**Acknowledgments:** We wish to acknowledge the contribution made by the primary care physicians and their team members who conducted the study in their centres.

**Disclosure of Interests:** Hazylna Baharudin speaks to, and receives honoraria for, Sanofi, and is a member of the Remicade steering committee. The other authors have declared no conflict of interest.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.1679

AB0919 WHAT IS LOWEST EXTREMITY ENTHEOSEAL INVOLVEMENT IN ACUTE GOUT ATTACK? AN ULTRASOUND-STUDY

H. Cao1, G. Xu2, J. Lin1. 1The First Affiliated Hospital, College of Medicine, Zhejiang University, Rheumatology, Hangzhou, China; 2The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

**Background:** Gout and CPPD are paradigms for auto-inflammatory diseases. Gout is characterised by deposition of monosodium urate crystal in tophaceous gout. ULTRASOUND-STUDY

10.1136/annrheumdis-2020-eular.4138

Downloaded from http://ard.bmj.com/ on September 22, 2023 by guest. Protected by copyright.
Background: Articular involvement in acute gout attack is extremely common and mainly characterized by arthritis, which are usually transient, severe, reversible and well responsive to treatment. The involvement of tendons and entheses in lower extremity is also important and partially determines the outcome of the disease. To evaluate ultrasound (US) findings in gout, several studies have been performed by independent rheumatologists on gout patients. Assessment of tendons and entheses by US has been used in clinical practice since 1995. In our study, we aimed to evaluate the frequency and characteristics of tendon and enthesis involvement by US in a consecutive group of patients with acutely flared gout.

Objectives: To evaluate by ultrasound (US) the frequency and characteristics of lower extremity entheseal involvement in acute gout attack patients.

Methods: US assessment were performed by independent rheumatologist on 35 patients with acute gout attack. Presence of lower extremity entheseal involvement were evaluated by grey-scale (GS) and power Doppler (PD). US assessment contain quadriceps, patellar and Achilles tendons, and plantar fascia entheses according to the OMERACT definitions.

Results: US revealed one or more abnormalities in at least one enthesis in 22 out of 31 gout patients (71%) and 47 out of 51 entheses (92%). Among the affected entheses, the patellar insertion of quadriceps tendon was most commonly involved (57.4%) during acute gout attack, followed by the calcaneal insertion of the Achilles tendon (17%) and distal insertion of the patellar tendon (14.9%). The proximal insertion of the patellar tendon and calcaneal insertion of the plantar fascia were involved in 8.5% and 2.1%, respectively. Bone erosions and osteophytes were found in affected entheses (10.6% and 25.5%, respectively).

Conclusion: Our study identifies that lower extremity entheseal involvement is a missing target in the evaluation of patients with acute gout attack. US plays a key role in the assessment of both clinical and subclinical enthesis in gout patients.

References:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2020-eular.4138

Application of the EULAR 2016 Guidelines for Urate-Lowering Therapy in Clinical Practice (Data of a Six-Month Prospective Study)

M. Chikina1, M. Elesseev1, O. Sheliabina1, V.A. Nasonova Research Institute of Rheumatology, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: The EULAR 2016 guidelines on gout management provide for a consecutive regimen of urate-lowering medications; however, the possibility of reaching the target uric acid level when using the regimen has not been studied in clinical practice.

Objectives: To assess the possibility of reaching the target uric acid level when following the EULAR 2016 guidelines on gout management with use of different xanthine oxidase inhibitors available in Russia.

Methods: This monocentric prospective study included 83 gout patients (79 (95%) male and 4 (5%) female patients) with the mean age of 51.3±10.9 years old. The inclusion criteria were indications for urate-lowering therapy in accordance with the EULAR 2016 guidelines. The exclusion criteria were: absolute contraindications to all of the study drugs, GFR <30ml/min/1.73m2, and NYHA class III-IV heart failure.

At urate-lowering therapy initiation, the patients were prescribed allopurinol with the starting dose of 100mg/day; the dose was titrated until the target uric acid level was reached (maximum up to 900mg/day), and in the patients with GFR between 30 and 60ml/min/1.73m2 – up to 300mg/day. In case of insufficient efficacy of allopurinol (unachieved target uric acid level of <360µmol/L, for the patients with severe gout of <300µmol/L), or development of adverse reactions, allopurinol was replaced with febuxostat with the starting dose of 80mg/day and dose titration up to 120mg/day if necessary. The laboratory tests included serum creatinine level, uric acid level, AST, ALT, creatine phosphokinase, glucose; clinical blood test. The following parameters were assessed: possibility of reaching the target uric acid level when following the suggested regimen, and frequency of development of adverse reactions when using allopurinol and febuxostat.

Results: 37 (45%) patients had the target uric acid level of <360µmol/L and 46 (55%) pts – of <300µmol/L. The recommended therapy regimen allowed 77 (93%) patients under study to reach their target uric acid level.

The target uric acid level was achieved by 44 (53%) out of 79 patients on allopurinol, of whom 36 (82%) received 100-600mg/day, and 8 (18%) – 700-900mg/day. Of the patients with GFR of >60ml/min/1.73m2, 32 (73%) patients achieved their target uric acid level and of those with GFR <60ml/min/1.73m2 – so did 12 (27%). The starting dose of the febuxostat with initial uric acid level ≤ 8.5mg/dl was 20mg/day, and in the patients with uric acid level < 6.5mg/dl – 40mg/day. The target uric acid level was achieved in 19 (58%) patients, therefore, total 33 (85%) patients reached their target uric acid level. Four patients on febuxostat developed adverse reactions: 3 patients had a more than doubled serum transaminase level (ALT, AST) and 1 patient had hives. Also, an insignificant increase in the mean GFR was registered from 73±21.4ml/min/1.73m2 to 78±4.22±5.3ml/min/1.73m2 which did not differ between the two groups.

Conclusion: The recommended regimen of xanthine oxidase inhibitors in their maximal doses secures reaching the target uric acid level in 93% patients. In 47% patients, allopurinol in maximal doses (up to 900mg/day) did not significantly increase the possibility of reaching the target uric acid level, even though it demonstrates high tolerance.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2020-eular.5171

Comparison of Efficacy and Safety of Different Anti-Inflammatory Drugs as an Initiation of Urate-Lowering Therapy in Patients With Gout (Preliminary Data)

M. Chikina1, M. Elesseev1, V.A. Nasonova Research Institute of Rheumatology, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: NSAIDs, colchicine and glucocorticoids are used for prevention of acute arthrits in gout patients, yet there is little data on their comparative efficacy.

Objectives: Comparison of efficacy and safety of different anti-inflammatory drugs used for prevention of acute arthrits at initiation of urate-lowering therapy in gout patients.

Methods: This monocentric prospective study included 79 gout patients (75 (94.9%) male and 4 (5.1%) female patients) with the mean age of 51±10.9 years old. The inclusion criteria were: established gout (ACR/EULAR 2015 criteria), aged 18-80, serum uric acid level >360µmol/L, absence of urate-lowering therapy at baseline and at least one gout flare within past three months. The exclusion criteria were: absolute contraindications to all of the study drugs, GFR <30min/ml/1.73m2. All of the patients were prescribed urate-lowering therapy (allopurinol or febuxostat), the dose was titrated until the target serum uric-acid level (<360µmol/L) was achieved. Simultaneously, preventive anti-inflammatory therapy was initiated and the drug for each patient was chosen individually: colchicine 0.5mg/day or any NSAID in minimal anti-inflammatory dose or prednisolone 7.5mg/day. The analysis of the data included 3-month comparative evaluation of the efficacy of the preventive therapy against the following parameters: frequency of gout flare and pain intensity thereof, VAS pain intensity of flare. The laboratory tests included serum creatinine level, uric acid level, AST, ALT, creatine phosphokinase, glucose; clinical blood test before, two weeks and three months after the initiation of the therapy.

Results: NSAIDs were received by 14 (17.7%) patients, colchicine by 56 (70.9%) and glucocorticoids by 9 (11.4%) patients. There were no differences initially in age, GFR or lab test values.

Three months later, the gout flares frequency median lowered to 1 [0;2] flare (p<0.01). The frequency of gout flares did not depend on the chosen drug and was 1 [0;1] for NSAIDs, 1 [0;2] for colchicine and 1 [1;2] for glucocorticoids. 40 (50.5%) patients out of 79 did not have a single flare. The patients who received NSAIDs (57.1%) and colchicine (42.9%) experienced no gout flares more often than those who received glucocorticoids (37.5%), but the differences were not significant. However, the VAS pain intensity of gout flares in the patients who received NSAIDs (30.7±12.9mm) was lower than in those who received colchicine (42.1±12.3mm) and glucocorticoids (42.2±8.4mm) (p<0.05 for both). The duration of gout flares on different drugs was not significantly different and was on average 3 [1.5;4] days for the patients on NSAIDs, 5 [3;7] days for those on colchicine and 5 [4;6] days for the patients on glucocorticoids.

The NSAID therapy was discontinued in two cases, in which the serum transaminase levels (AST, ALT) more than doubled; the colchicine therapy - because of development of diarrhea in two patients and of myopathy in one.

Conclusion: Efficacy of and tolerance to a three-month course of preventive therapy with different anti-inflammatory drugs in gout patients is comparable to each other, however, efficacy of colchicine is significantly higher.